Insider buying last 90 days
No open-market insider purchases were filed for RMD in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every RMD insider filing, plotted on the chart in Gekko.Open RMD in Gekko
Gekko Brief
Nov 4 closeResMed closed at $240.51 on 4 November 2026, +5.9% on the day. The price sits above both the 50-day ($231.79) and 200-day ($224.53) moving averages, inside a 52-week range of $180.27 to $277.67. The GekkoIndex reads 58.3, in the Neutral zone, up 13.5 points over five sessions. Gekko Fair Value is $296.05, so the price is 18.8% below it.
The next earnings report is due on 28 January 2027, 84 days away (after close). Over the last 8 reports the company beat the earnings estimate 6 times, with an average move of 4.7% across the report. Smart-money activity over the last 90 days includes 1 Congress purchase and 0 sales. Seasonally, the next 20 trading days from this point averaged +2% over the last 5 years, rising in 4 of them.
14 firms rate the stock: 5 buy, 9 hold and 0 sell, with a consensus target of $265.11. A typical daily move is about 3.4%, and a typical 20-day move about 4.9%. On the swing-trade checklist, 5 items read supportive and 0 read as a headwind.
A plain summary of the figures as of the Nov 4, 2026 close.
ResMed price vs fair value
Close $240.51200-day averageGekko Fair Value $296.05
ResMed quick facts
- Market cap
- $33.83B
- P/E ratio
- 21.2
- Forward P/E
- 19.2
- EPS, TTM
- $10.98
- Revenue, TTM
- $5.73B
- Profit margin
- 27.8%
- Dividend yield
- 1.07%
- Beta
- 0.76
- Volume
- 2.24M avg 1.37M
- 1-year return
- −3.4%
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±4.9%
- 50-day average
- $231.79
- 200-day average
- $224.53
- Next earnings
- Jan 28 after close
- Shares outstanding
- 140.7M
ResMed swing-trade checklist
ResMed scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive1 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $240.51 is above the 50-day ($231.79) and 200-day ($224.53) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
58.3, Neutral
Reading 58.3 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
18.8% below
Price is 18.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings risksupportive
Reports in 84 days
Next report Jan 28, 2027, 84 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+2.0% on average
From this point in the calendar, the next 20 trading days averaged +2% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
ResMed stock chart and price history
ResMed closed at $240.51 on Nov 4, 2026, −3.4% over the past year, inside a 52-week range of $180.27 to $277.67.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +9.0%
- 3 months
- +7.7%
- 6 months
- +14.7%
- 1 year
- −3.4%
The full RMD chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RMD in Gekko
Follow ResMed through every session
Put RMD on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track RMD in GekkoFree for 7 days. No credit card required.
About ResMed
ResMed designs, builds and sells medical devices and connected digital tools aimed at people with respiratory conditions, particularly sleep apnea. Its equipment lineup spans ventilators, diagnostic machines, masks and headgear for both clinical and home use, along with dental devices. The company is also known for pairing this hardware with software that helps clinicians and patients track therapy and manage care remotely.
The business is organized into two segments, one covering sleep and respiratory care hardware and the other focused on software delivered as a service. On the software side, tools such as AirView let providers monitor devices remotely, myAir helps patients stay engaged with their own therapy, and U-Sleep tracks compliance for home medical equipment suppliers. ResMed also runs platforms like Brightree, MatrixCare and HEALTHCAREfirst, which support home care providers, senior living and hospice organizations, and home health agencies with business management, care coordination and records. Its customers include sleep clinics, home healthcare dealers and hospitals, reached through a direct sales force and distributors across roughly 140 countries.
ResMed was founded in 1989 and is headquartered in San Diego, California. Its shares are listed on the NYSE under the ticker RMD.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- resmed.com
ResMed GekkoIndex: the smart money zone
ResMed’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.3, in the Neutral zone, up 13.5 points over five sessions.
58.3Neutral
Up 13.5 points over five sessions, from the Distribution zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 40 | +1.0% | +3.1% | ||
| Accumulation | 224 | +0.9% | +1.5% | ||
| Neutral (current zone) | 389 | 0.0% | +0.9% | ||
| Distribution | 38 | −1.3% | −2.8% | ||
| Selling | 6 | Too few readings yet | |||
Average RMD share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the RMD price, zone by zone.Track RMD in Gekko
Is ResMed stock overvalued? Gekko Fair Value
ResMed trades 18.8% below Gekko Fair Value of $296.05, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what ResMed shares are worth, recalculated every trading day.
$296.05
Gekko Fair Value, Nov 4, 2026
18.8% Undervalued
At the end of Aug 2026 the price was 19.2% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open RMD in Gekko
ResMed insider and Congress trading
No open-market insider purchases were filed for ResMed, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 11 |
From congressional disclosures, which report amounts as ranges.
Buybacks
ResMed has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2026
- $936.4M
- As a share of market cap
- 2.77%
- Trailing four quarters
- $1.99B
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold RMD.
0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
ResMed earnings: next date and track record
ResMed reports on Jan 28, 2027, after the close (84 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Jan 28, 2027
Expected after the close, 84 days away
- EPS estimate
- $3.02
- Revenue estimate
- $1.46B
6 of 8reports beat the EPS estimate
±4.7%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 29, 2026 AI summary
- What they said
- ResMed reported Q1 FY2027 results with 7% core constant currency revenue growth, 50 basis points of gross margin expansion, and 14% non-GAAP EPS growth. The company returned over $1 billion to shareholders via dividends and buybacks using MatrixCare divestiture proceeds. Key launches include AirCurve 11 ST/ST-A bilevel devices, the AirTouch F40 fabric mask (91% comfort rating, 6% better adherence vs silicone), and a refreshed myAir app with 13M+ downloads.
- Guidance
- Management describes FY2027 as off to an excellent start with focus on innovation, portfolio management, and capital allocation. No specific revenue or EPS targets were provided in this excerpt, but the company signals continued growth investment and shareholder returns.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $2.91 est $2.69 | $1.41B est $1.39B | −8.1% |
| Aug 6, 2026 | $2.95 est $2.90 | $1.46B est $1.46B | −5.4% |
| Apr 30, 2026 | $2.86 est $2.78 | $1.43B est $1.42B | −3.3% |
| Jan 29, 2026 | $2.81 est $2.72 | $1.42B est $1.40B | +0.2% |
| Oct 30, 2025 | $2.55 est $2.51 | $1.34B est $1.33B | −2.7% |
| Jul 31, 2025 | $2.55 est $2.55 | $1.35B est $1.35B | +0.6% |
| Apr 23, 2025 | $2.37 est $2.38 | $1.29B est $1.29B | +10.3% |
| Jan 30, 2025 | $2.43 est $2.31 | $1.28B est $1.27B | −6.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
ResMed stock forecast and analyst price targets
Analysts’ average 12-month price target for ResMed is $265.11, +10.2% from the last close, from 14 firms rating the stock in the last 90 days.
$265.11consensus 12-month target, +10.2% from the last close
Now $240.51Avg $265.11
Low $230High $320
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Citi | $270 | +12.3% |
| Nov 2 | Bank of America Securities | $320 | +33.1% |
| Oct 30 | KeyBanc | $277 | +15.2% |
| Oct 30 | Mizuho Securities | $270 | +12.3% |
| Oct 30 | Morgan Stanley | $233 | −3.1% |
+0.9%average 20-day move after past Neutral readings
+2.0%average move over the next 20 trading days in the last 5 years
±3.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
ResMed seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, ResMed averaged +2.0% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.1% | 3 of 5 |
| Next 10 trading days | +0.5% | 2 of 5 |
| Next 15 trading days | +1.7% | 3 of 5 |
| Next 20 trading days | +2.0% | 4 of 5 |
| Next 30 trading days | +1.2% | 1 of 5 |
For scale, RMD’s typical 20-trading-day move in either direction is about 4.9%.
ResMed market cap and key statistics
ResMed’s market cap is $33.83B, with a P/E ratio of 21.2 and revenue of $5.73B over the last twelve months.
Valuation
- Market cap
- $33.83B
- P/E ratio
- 21.2
- Forward P/E
- 19.2
- EPS, TTM
- $10.98
- Gekko Fair Value
- $296.05
Trading
- Volume
- 2.24M
- Avg volume, 20 days
- 1.37M
- 52-week high
- $277.67
- 52-week low
- $180.27
- Shares outstanding
- 140.7M
Financials
- Revenue, TTM
- $5.73B
- Profit margin
- 27.8%
- Return on equity
- 26.4%
- Quarterly earnings growth, YoY
- +23.2%
Risk and income
- Beta
- 0.76
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±4.9%
- Dividend yield
- 1.07%
ResMed stock news this week
Coverage of ResMed this week reads positive: 15 positive, 8 neutral and 1 negative headlines.
- ResMed Inc. $RMD Shares Sold by Sumitomo Mitsui Trust Group Inc.MarketBeat, Nov 4
- ResMed Inc. (RMD) Stock forecastsYahoo Finance UK, Nov 4
- ResMed Inc Reports Net Reduction of 10,680,280 CDIs on Issue for October 2026Kalkine, Nov 4
- ResMed Inc. stock rises Monday, outperforms marketMarketWatch, Nov 2
- ResMed Inc. Just Recorded A 13% EPS Beat: Here's What Analysts Are Forecasting NextSimply Wall St, Nov 2
- ResMed Inc. (RMD.AX) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada, Nov 2
ResMed peers
ResMed’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 14.5% above |
| ABTAbbott Laboratories | Distribution | 8.0% below |
| ISRGIntuitive Surgical | Distribution | 30.4% above |
| DHRDanaher | Neutral | 3.6% above |
| MDTMedtronic | Neutral | 16.0% below |
| SYKStryker | Distribution | 6.5% above |
A peer links to its own page where one exists.
ResMed stock FAQ
What is ResMed’s market cap?
ResMed’s market cap is $33.83B at the Nov 4, 2026 close of $240.51, with 140.7M shares outstanding. The shares trade on a P/E ratio of 21.2.
What is the ResMed stock forecast?
The consensus analyst 12-month price target for ResMed is $265.11, +10.2% from the last close. Of the 14 firms that rated the stock in the last 90 days, 5 rate it a buy, 9 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is ResMed stock overvalued or undervalued?
On Gekko’s estimate ResMed is undervalued: the Nov 4, 2026 close of $240.51 is 18.8% below Gekko Fair Value of $296.05. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does ResMed report earnings next?
ResMed is expected to report on Jan 28, 2027, after the market closes (84 days away). Analysts expect earnings of $3.02 per share on revenue of $1.46B. ResMed beat the earnings estimate in 6 of its last 8 reports, moving 4.7% on average across the report.
What is ResMed’s 52-week high and low?
ResMed’s 52-week high is $277.67 and its 52-week low is $180.27; it closed at $240.51 on Nov 4, 2026, −3.4% over the past year. Over the last five years the shares peaked at $293.81 on Aug 22, 2025.
Is ResMed stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (trend, fair value, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See ResMed the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.